Bibliography
- Pellacani A , BrunnerHR, NussbergerJ: Plasma kinins increase after angiotensin enzyme inhibition in human subjects.Clin. Sci. (Lond.)87 , 567–574 (1994).
- Ferrari R : Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.Expert Rev. Cardiovasc. Ther.3 , 15–29 (2005).
- Brugts JJ , den Uil CA, Danser AHJ, Boersma E: The renin–angiotensin–aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology112 , 303–312 (2009).
- Pfeffer MA , BraunwaldE, SAVE Investigators et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med.327 , 669–677 (1992).
- The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325 , 293–302 (1991).
- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342 , 821–828 (1993).
- Torp-Pedersen C , Kober L; TRACE Study Group: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet354 , 9–12 (1999).
- The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342 , 145–153 (2000).
- The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351 , 2058–2068 (2004).
- The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet362 , 782–788 (2003).
- The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology: Guidelines on the management of stable angina pectoris. Eur. Heart J.27 , 1341–1381 (2006).
- Wood D , DeBackerG, FaergamO, GrahamI, ManciaG, PyöräläK and the task force: Prevention of coronary disease in clinical practice: recommendation of the second Joint Task Force of European and other societies on Coronary Prevention. Atherosclerosis140 , 99–270 (1998).
- Gibbons RJ , AbramsJ, ChatterjeeK et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).J. Am. Coll. Cardiol.41 , 159–168 (2003).
- Brugts JJ , FerrariR, SimoonsML: Angiotesin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.Exp. Rev. Cardiovasc. Ther.7(4) , 345–360 (2009).
- Bots ML , RemmeWJ, LüscherTF et al.: ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.Cardiovasc. Drugs Ther.21 , 269–279 (2007).
- Rodriguez-Granillo GA , VosJ, De Feyter PJ: Long-term effect of perindopril on coronary atherosclerosis progression (from the Perindopril‘s Prospective Effect on Coronary aTherosclerosis by Angiography and Intravascular Ultrasound Evaluation [PERSPECTIVE] Study). Am. J. Cardiol.100 , 159–163 (2007).
- Ceconi C , FoxKM, FerrariR et al.: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.Cardiovasc. Res.73 , 237–246 (2007).
- Remme WJ , DeckersJW, FoxKM, FerrariR, BertrandM, Simoons ML; for the EUROPA Investigators: Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc. Drugs Ther.23(2) , 161–170 (2009)
- Dagenais GR , PogueJ, FoxK, SimoonsML, YusufS: Angiotensin converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.Lancet368 , 581–588 (2006).
- Deckers JW , GoedhartDM, BoersmaE et al.: Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.Eur. Heart J.27 , 796–801 (2006).
- Brugts JJ , KnetschAM, Mattace-RasoFU, HofmanA, WittemanJC: Renal function and risk of myocardial infarction in an elderly population: the Rotterdam study.Arch. Intern. Med.165 , 2659–2665 (2005).
- Brugts JJ , BoersmaE, ChoncholM et al.: The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.J. Am. Coll. Cardiol.50 , 2148–2155 (2007).
- Brugts JJ , NinomiyaT, BoersmaE et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.Eur. Heart J.30 , 1385–1394 (2009).
- Danser AHJ , SchunkertH: Renin–angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases.Eur. J. Pharmacol.410 , 303–316 (2000).
- Brugts JJ , de Maat M, den Uil CA et al.: Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr. Opin. Cardiol.23 , 296–301 (2008).
- Simon T , VerstuyftC, Mary-KraueM et al.; for the FAST-MI Investigators: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360 , 363–375 (2009).
- The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy, a genome wide study. N. Engl. J. Med.359 , 789–799 (2008).
- International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8) , 753–764 (2009).
- Arnett DK , DavisBR, FordCE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.Circulation111 , 3374–3383 (2005).
- PROGRESS Collaborative Group: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension42 , 297–303 (2003).
- Su X , LeeL, LiX et al.: Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor.Circulation115 , 725–732 (2007).
- Brugts JJ , de Maat M, Boersma E et al.: The rationale and design of the Perindopril Genetic Association Study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther.23 , 171–181 (2009).
- van der Net JB , van Etten J, Yazdanpanah M et al.: Gene-load score of the renin–angiotensin–aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia. Eur. Heart J.29(11) , 1370–1376 (2008).
- Brugts JJ , IsaacsA, BoersmaE et al.: Genetic determinants of treatment benefit of angiotensin-converting enzyme-inhibitor therapy in patients with stable coronary artery disease.Eur. Heart J.31(15) , 1854–1864 (2010).
- Merino VF , TodirasM, MoriMA et al.: Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.J. Mol. Med.87(10) , 953–963 (2009).
- Luft FC : Aneurysm formation and bradykinin.J. Mol. Med.87(10) , 941–943 (2009).
- Gainer JV , MorrowJD, LovelandA, KingDJ, BrownNJ: Effect of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects.N. Engl. J. Med.339 , 1285–1292 (1998).
- Xu J , CarreteroOA, SheselyEG et al.: The kinin B1 receptor contributes to the cardioprotective effect of ACE inhibitors and angiotensin receptor blockers.Exp. Physiol.94(3) , 322–329 (2009).
- Marin-Castaño ME , SchanstraJP, NeauE et al.: Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment.Circulation5 , 627–632 (2002).
- Ignatovic T , TanF, BrovkovychV, SkidgelRA, ErdosGE: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of the bradykinin receptor type I.J. Biol. Chem.277 , 16847–16852 (2002).
- Ignjatovic T , StanisavljevicS, BrovkovychV, SkidgelRA, ErdosEG: Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands.Mol. Pharmacol.66 , 1310–1316 (2004).
- Forten JP , GobeilF Jr, Adam A, Regoli D, Marceau F: Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor? Am. J. Physiol. Heart Circ. Physiol.285 , H277–H282 (2003).
- Su JB , HoüelR, HéloireF et al.: Stimulation of bradykinin B1 receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs.Circulation101 , 1848–1853 (2000).
- Austinat M , BraeuningerS, PesqueroJB et al.: Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema.Stroke40 , 285–293 (2009).
- Brugts JJ , YetginT, HoeksS et al.: The benefit of HMG CoA reductase inhibitors in patients without established cardiovascular disease with cardiovascular risk factors.BMJ338 , b2376 (2009).